Last reviewed · How we verify
individual adapted immunosuppression
At a glance
| Generic name | individual adapted immunosuppression |
|---|---|
| Sponsor | University Hospital, Ghent |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders (PHASE2)
- Cardiac Allograft Remodeling and Effects of Sirolimus (PHASE1)
- Improving ImmunoSuppression Adherence After Liver or Kidney Transplantation (NA)
- Project 4A: Inspiratory Muscle Training and Diaphragm Strength (PHASE1, PHASE2)
- Individually Adapted Immunosuppression in de Novo Renal Transplantation Based on Immune Function Monitoring: a Prospective Randomised Study (PHASE4)
- Study Comparing Effect On Carotid Atherosclerosis Following Conversion From Tacrolimus To Sirolimus Post-Transplant In Kidney Transplant Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- individual adapted immunosuppression CI brief — competitive landscape report
- individual adapted immunosuppression updates RSS · CI watch RSS
- University Hospital, Ghent portfolio CI